Issue 5/2012

  • It's finally spring for EU biotechs

    In this issue:

    • Austrian efforts to implement a total national ban on GMOs
    • Finland's UPM invests €150m in biodiesel refinery
    • AstraZeneca to take over US gout drug specialist Ardea
    • SPECIAL: Contract Research – Opportunities for outsourcing
    • Cancer start-up Vivia Biotech secures Series B financing 
    • Gedeon Richter opens huge biologics manufacturing plant
    • Databases link cancer cell genomics to drug efficacy

Volume 2016

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/5/pos/1.html?cHash=8305edff5982cb307c5ea48106acb36a&sort=desc

Kurszettel

Alle Kurse

TOP

  • METABOLIC EXPLORER (F)2.26 EUR17.10%
  • CERENIS THERAPEUTICS HOLDING SA (F)8.09 EUR7.72%
  • MOLMED (I)0.42 EUR7.69%

FLOP

  • PHOTOCURE (N)46.40 NOK-8.12%
  • VERNALIS (UK)43.00 GBP-4.44%
  • E-THERAPEUTICS (UK)11.75 GBP-4.08%

TOP

  • DIAMYD MEDICAL -B- (S)7.05 SEK67.9%
  • KARO BIO (S)38.30 SEK33.4%
  • NEWRON (CH)20.65 CHF24.8%

FLOP

  • BIONOR PHARMA (N)0.47 NOK-23.0%
  • NOVOZYMES (DK)284.10 DKK-14.4%
  • WILEX (D)1.53 EUR-12.6%

TOP

  • KARO BIO (S)38.30 SEK2453.3%
  • NICOX (F)10.33 EUR470.7%
  • SAREUM HOLDINGS (UK)0.74 GBP252.4%

FLOP

  • BB BIOTECH (D)46.45 EUR-80.4%
  • EVOCUTIS (UK)0.04 GBP-78.9%
  • NOVACYT (F)1.30 EUR-70.4%

No liability assumed, Date: 23.08.2016